CD353 (SLAMF8) Antibody, anti-human, APC, REAfinity™ | Miltenyi Biotec 130-106-734 product information

This webpage contains legacy information. The product is either no longer available from the supplier or has been delisted at Labome.

product summary

company name :

Miltenyi Biotec

product type :

antibody

product name :

CD353 (SLAMF8) Antibody, anti-human, APC, REAfinity™

catalog :

130-106-734

quantity :

30 tests in 300 µL

price :

138 USD

clonality :

monoclonal

host :

human

conjugate :

APC

clone name :

REA394

reactivity :

human

application :

immunohistochemistry, immunocytochemistry, flow cytometry

citations: 3

Reference
Wang G, Abadia Molina A, Berger S, Romero X, O Keeffe M, Rojas Barros D, et al. Cutting edge: Slamf8 is a negative regulator of Nox2 activity in macrophages. J Immunol. 2012;188:5829-32 pubmed publisher
Matesanz Isabel J, Sintes J, Llinàs L, de Salort J, Lázaro A, Engel P. New B-cell CD molecules. Immunol Lett. 2011;134:104-12 pubmed publisher
Kingsbury G, Feeney L, Nong Y, Calandra S, Murphy C, Corcoran J, et al. Cloning, expression, and function of BLAME, a novel member of the CD2 family. J Immunol. 2001;166:5675-80 pubmed

product information

MB Cataloge Number :

130-106-734

Catalog Number :

130-106-734

Product Name :

CD353 (SLAMF8) Antibody, anti-human, APC, REAfinity™

Product Type :

Primary antibodies, Recombinant antibodies

Host Species :

recombinant human IgG1

Clonality :

monoclonal

Conjugation :

APC

Antigen Modification :

CD353 (SLAMF8)

Clone Name :

REA394

Isotype :

REA Control Antibody (S), human IgG1

Size :

30 tests in 300 µL

US List Price :

138 USD

Product Description :

Identification and enumeration of CD353 (SLAMF8)+ cells by flow cytometry

ALTnames :

SLAMF8, BLAME, SBBI42

Specificity :

human

Concentration :

1:11

Uses :

For research use only

Application Summary :

Flow cytometry, MICS (MACSima Imaging Cyclic Staining), Immunohistochemistry, Immunofluorescence

Storage :

Store protected from light at 2–8 °C. Do not freeze.